Mentorship in Pulmonary Vascular Disease

肺血管疾病的指导

• 批准号: 10370102
• 负责人: Anna R Hemnes
• 金额: $ 11.46万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-01-01 至 2026-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10370102
• 关键词: Affect; Award; Basic Science; Bioinformatics; Blood Vessels; Career Mobility; Cessation of life; Classification; Clinic; Clinical; Clinical Research; Clinical Trials; Data; Development; Diagnosis; Disease; Disease Marker; Educational workshop; Faculty; Funding; Goals; Grant; Guidelines; Human; Insulin Resistance; International; Intervention; Lead; Lipids; Lung; Lung diseases; Measures; Mentors; Mentorship; Metabolic; Metabolic Diseases; Metabolic dysfunction; Metformin; Mid-Career Clinical Scientist Award (K24); Midcareer Investigator Award in Patient-Oriented Research; Molecular; National Heart, Lung, and Blood Institute; Outcome; Pathogenesis; Patients; Phenotype; Play; Postdoctoral Fellow; Predisposition; Program Research Project Grants; Prospective cohort; Publications; Pulmonary Hypertension; Recording of previous events; Research; Research Personnel; Research Project Grants; Research Training; Resources; Right Ventricular Dysfunction; Role; Scientist; Severity of illness; Techniques; Testing; Time; Training; United States; United States National Institutes of Health; Work; base; career; career development; clinical phenotype; cohort; effective therapy; experience; improved; large datasets; member; molecular phenotype; mortality; next generation; novel therapeutics; patient oriented; patient oriented research; precision medicine; programs; pulmonary arterial hypertension; pulmonary vascular disorder; recruit; resilience; response; right ventricular failure; skills; student mentoring; training opportunity; treatment response; treatment strategy; working group

Pulmonary arterial hypertension (PAH) is a rare lung disease characterized by progressive pulmonary vascular obliteration resulting in right ventricular failure and ultimately death. Throughout the last three decades there has been tremendous progress in understanding disease mechanisms that have led to new therapies, however survival remains poor at approximately 8 years after diagnosis for most patients. There have been several recent NIH/NHLBI sponsored workshops on phenotyping patients with PAH and moving accumulating “Omic” data into the clinic to advance precision medicine in PAH, yet there are few centers in where this work is ongoing and training the next generation of researchers in these techniques will be critically important to advancing the field of PAH therapy and pulmonary vascular disease more broadly. Dr. Hemnes is a well- recognized expert in this field and her objective is to use the support of the K24 Midcareer Investigator Award in Patient-Oriented Research to focus on training the next generation of scientists to bring precision medicine approaches to PAH patient therapy. The candidate’s immediate and long-term career objectives are directly in line with the goals of the NIH K24 award, to provide support for protected time for awardees to devote to patient-oriented research and culturally-sensitive mentoring for students, residents, fellows and junior faculty. Specifically, this award will allow her to focus on the development of (1) a patient-oriented research program in pulmonary vascular disease research and (2) a mentoring program to facilitate the career development of new investigators. This award will provide protected time for the candidate to devote specifically to developing mentoring skills in patient-oriented research. Her objective is to recruit and mentor students, residents, fellows and junior faculty for successful clinical research careers in pulmonary vascular disease and to support the career advancement of her current trainees who are fellows and junior faculty members. To expand her patient-oriented research program in PAH, she will combine two lines of study in her research portfolio (1) understanding how insulin resistance in the lipid axis may predispose to PAH or affect outcomes and (2) using Omic techniques to deep phenotype patients with pulmonary vascular disease. The proposal here will build on her funded work to test the hypothesis that Omic signatures in PAH can identify features of resilience to PAH progression and metabolic intervention susceptibility. The specific aims are (1) To compare PAH patients with and without Omic signatures of metabolic dysfunction, define differences in clinical and molecular features and measure relevant outcomes between the two groups, (2) To test and validate Omic predictors of metformin responses in completed and ongoing clinical trials in PAH patients. Completion of these aims will enhance understanding of the pathogenesis of PAH and uncover potentially improved treatment strategies of metabolic disease in PAH specifically. The proposed new research, along with the candidate’s other funded research projects, will provide invaluable training opportunities in patient-oriented pulmonary vascular disease research.

肺动脉高压（PAH）是一种罕见的肺部疾病， 闭塞导致右心室衰竭并最终死亡。在过去的三十年里， 然而，在理解疾病机制方面取得了巨大进展，导致了新的疗法， 大多数患者在诊断后约8年的生存率仍然很低。发生了几 最近NIH/NHLBI赞助了关于PAH患者表型分型和移动累积“Omic”的研讨会 数据进入临床，以推进PAH的精准医学，但很少有中心开展这项工作。 持续和培训下一代研究人员在这些技术将是至关重要的， 更广泛地推进PAH治疗和肺血管疾病领域。赫姆尼斯医生是个... 她是该领域公认的专家，她的目标是利用K24职业中期研究者奖的支持 以患者为导向的研究，重点是培养下一代科学家， PAH患者治疗方法。候选人的近期和长期职业目标直接体现在 符合NIH K24奖的目标，为获奖者提供受保护的时间，以致力于 以病人为导向的研究和对学生，居民，研究员和初级教师的文化敏感的指导。 具体而言，该奖项将使她能够专注于（1）以患者为导向的研究计划的发展， 肺血管疾病研究和（2）辅导计划，以促进新的职业发展 investigators.该奖项将为候选人提供受保护的时间，专门用于开发 在以病人为导向的研究中的指导技能。她的目标是招募和指导学生，居民，研究员 和初级教师成功的临床研究事业在肺血管疾病，并支持 她目前的学员谁是研究员和初级教员的职业发展。扩大她 在PAH患者为导向的研究计划，她将联合收割机在她的研究组合（1）两条线的研究 了解脂质轴中的胰岛素抵抗如何易患PAH或影响结局，以及（2）使用 Omic技术在深表型肺血管病患者中的应用。这里的建议将建立在 她资助的工作是测试PAH中的Omic签名可以识别PAH弹性特征的假设 进展和代谢干预易感性。具体目的是（1）比较PAH患者与 和没有代谢功能障碍的Omic特征，定义临床和分子特征的差异， 测量两组之间的相关结果，（2）检验和验证二甲双胍的OMIC预测因子 PAH患者中已完成和正在进行的临床试验中的缓解。这些目标的实现将促进 了解PAH的发病机制，并发现潜在的代谢性疾病的治疗策略 尤其是PAH。拟议的新研究，连同候选人的其他资助研究，沿着 项目，将提供宝贵的培训机会，以病人为导向的肺血管疾病的研究。